CTRI/2009/091/000288招募中3 期
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects with Schizophrenia (PEARL 3)
Dainippon Sumitomo Pharma America, Inc., One Bridge Plaza, Suite 510, Fort Lee, NJ 07024, USA0 个研究点目标入组 480 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Main Inclusion Criteria:
- •Subject is 18 to 75 years of age on the day of signing informed consent.
- •Subject meets DSM-IV-TR criteria for a primary diagnosis of schizophrenia (including disorganized (295.10), paranoid (295.30), or undifferentiated (295.90) subtypes as established by clinical interview (using the Mini-International Neuropsychiatric Interview [MINI] Plus diagnostic interview and the DSM-IV-TR as a reference). The duration of the subject?s illness whether treated or untreated must be greater than 1 year.
- •Subject has an acute exacerbation of psychotic symptoms (no longer than 2 months) and marked deterioration of function from baseline (by history) or subject has been hospitalized for the purpose of treating an acute psychotic exacerbation for 2 consecutive weeks or less immediately before screening. Subjects who have been hospitalized for more than 2 weeks for reasons unrelated to acute exacerbation can be included with concurrence from the Medical Monitor that such hospitalization was for a reason other than acute relapse. For example, subjects in long-term hospitals (e.g., for years) who have a clear acute exacerbation and are transferred to an acute unit (for 2 weeks or less) are suitable for this protocol.
- •Subject has a PANSS total score ≥80 at screening and baseline, with a score ≥4 (moderate) on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content.
- •Subject has a score ≥4 on the CGI-S at screening and baseline.
- •Subject is able and agrees to remain off prior antipsychotic medication for the duration of the study.
- •Subject has had a stable living arrangement for at least 3 months prior to randomization and agrees to return to a similar living arrangement after discharge. This criterion is not meant to exclude subjects who have temporarily left a stable living arrangement (e.g., due to psychosis). Such subjects remain eligible to participate in this protocol. Chronically homeless subjects should not be enrolled. The Medical Monitor should be consulted for individual cases as needed.
排除标准
- •Main Exclusion Criteria
- •Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
- •Subject has a prolactin concentration >100 ng/mL at screening or has a history of pituitary adenoma.
- •Subject has a history of hypersensitivity to quetiapine.
- •Subject has used quetiapine within 30 days prior to Screening and/or has a history of inadequate response or intolerability to quetiapine.
- •Subject is resistant to neuroleptic treatment, defined as failure to respond to 2 or more marketed antipsychotic agents from 2 different classes, given at an adequate dose for at least 6 weeks.
- •Subject has received depot neuroleptics unless the last injection was at least 1 treatment cycle before randomization.
- •Subject has a history of treatment with clozapine for refractory psychosis and/or subject has been treated with clozapine (for any reason) within 4 months of randomization.
- •Subject has received treatment with mood stabilizers or antidepressants within 1 week, fluoxetine hydrochloride at any time within 1 month, or a monoamine oxidase (MAO) inhibitor with 3 weeks of randomization.
- •Subject will require treatment with any potent cytochrome P450 3A4 (CYP3A4) inhibitors or inducers during the study. Subject requires treatment with a drug that prolongs the QT interval corrected for individual heart rate (QTc interval).
- •The subject demonstrates a decrease (improvement) of >20% in the PANSS score between the screening and baseline visits, or the PANSS score falls below 80 at baseline.
研究者
相似试验
尚未招募
3 期
DORADO-AC – Optimized Doses of Darusentan as Compared to an Active Control in Resistant HypertensioResistant HypertensionACTRN12606000446561Myogen, Inc.800
进行中（未招募）
1 期
A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients with Osteoarthritis of the Knee or Hiposteoarthritis of the knee and hipMedDRA version: 12.0Level: LLTClassification code 10020108Term: Hips osteoarthritisMedDRA version: 12.0Level: LLTClassification code 10023476Term: Knee osteoarthritisEUCTR2009-013329-41-FRPfizer Inc, 235 East 42nd Street, New York, NY 10017800
进行中（未招募）
不适用
A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients with Osteoarthritis of the Knee or HipEUCTR2009-013329-41-SEPfizer Inc, 235 East 42nd Street, New York, NY 10017800
进行中（未招募）
不适用
A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients with Osteoarthritis of the Knee or Hiposteoarthritis of the knee and hipMedDRA version: 12.0Level: LLTClassification code 10020108Term: Hips osteoarthritisMedDRA version: 12.0Level: LLTClassification code 10023476Term: Knee osteoarthritisEUCTR2009-013329-41-DKPfizer Inc, 235 East 42nd Street, New York, NY 10017800
进行中（未招募）
不适用
A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients with Osteoarthritis of the Knee or Hiposteoarthritis of the knee and hipMedDRA version: 12.0Level: LLTClassification code 10020108Term: Hips osteoarthritisMedDRA version: 12.0Level: LLTClassification code 10023476Term: Knee osteoarthritisEUCTR2009-013329-41-DEPfizer Inc, 235 East 42nd Street, New York, NY 10017800